Key result
Low-dose methylprednisolone triggers bradycardia in a pediatric COVID-19 case on arbidol via CYP3A4 inhibition.
Why the study?
Bradycardia associated with low dose methylprednisolone use in children with COVID-19, especially with concurrent long-term arbidol use, is not well recognized.
Does low dose methylprednisolone cause bradycardia in a child with COVID-19 on long-term arbidol?
Case Report (n=1)
Does low dose methylprednisolone cause bradycardia in a child with COVID-19 on long-term arbidol?
Low dose methylprednisolone can induce significant bradycardia in patients on long-term arbidol due to CYP3A4 competitive inhibition.
May signal bradycardia risk with low-dose MP plus arbidol in children; leaves open clinical relevance of this CYP3A4 interaction.
Methylprednisolone (MP) is usually used to reduce inflammation reaction and tissue damage, which may have a beneficial treatment effect on coronavirus disease 2019 (COVID-19). However, we present the case of a child who manifests significant bradycardia with the use of just low dose MP on the premise of the long-term use of arbidol. Arbidol can affect the activity of CYP3A4, which is also a key metabolic enzyme of MP by competitive inhibition, and which is easy to aggravate the side effects of MP. Therefore, more attention should be paid to bradycardia occurrence in the patient with COVID-19 when MP is considered in COVID-19.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2021) conducted a case report in COVID-19 (n=1). Low dose methylprednisolone was evaluated on Bradycardia. Low dose methylprednisolone induced significant bradycardia in a child with COVID-19 on long-term arbidol, likely due to competitive inhibition of CYP3A4.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: